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Background: Hepatic encephalopathy (HE) is a reversible complication of liver disease 
characterized by neuropsychiatric abnormalities ranging from mild cognitive impairment 
to coma. Several strategies, including prophylaxis with rifaximin and/or lactulose are 
recommended to prevent HE recurrence. While efficacy of rifaximin compared to placebo 
was demonstrated in clinical trials, there is limited evidence confirming real-world 
effectiveness. 
Objective: To assess the real-world effectiveness of rifaximin as prophylaxis for HE. 
Methods: This observational, retrospective, cohort study utilized existing electronic health 
record data at a large integrated delivery network (IDN) in Texas (2014–2020). Patients 
were indexed on the date of discharge from the first eligible HE-related hospitalization 
during the enrollment period and grouped based on the presence or absence of an active, 
outpatient medication order for rifaximin at discharge. Patient characteristics, 
comorbidities, labs, flowsheet data, and medication orders were collected at baseline. 
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Logistic regression was used to generate propensity scores (PS) and match patients to 
treatment groups. Proportions of patients with hospitalizations or emergency department 
(ED) visits classified by cause (HE-, liver-related, and/or all-cause) and time (30- and/or 
180-days post-index), and mortality were compared between treatment groups.  
Results: A total of 1,541 patients met all study criteria (N=390, rifaximin; N=1,151, 
control), of which 694 patients were PS-matched to treatment groups (N=347, both). 
Analysis of the PS-matched cohort showed no statistically significant differences between 
rifaximin and control in hospitalizations at 180 days (all: 58% vs. 56%, P=0.6451; liver: 
58% vs. 55%, P=0.5402; HE: 32% vs. 32%, P=0.9352), and 30 days (all: 31% vs. 29%, 
P=0.6191; liver: 30% vs. 29%, P=0.6171; HE: 14% vs. 14%, P=0.9128), or ED visits at 
180 days (all: 63% vs. 62%, P=0.7534; liver: 60% vs. 57%, P=0.5381; HE: 26% vs. 28%, 
P=0.4930) and 30 days (all: 35% vs. 35%, P=0.8113; liver: 33% vs. 31%, P=0.5675; HE: 
12% vs. 12%, P=0.8141), or mortality rates (19% vs. 20%; P=0.7723). 
Conclusion: After controlling for measurable covariates, patients discharged from an HE-
related hospitalization experienced no statistically significant differences in all-cause, 
liver-related, or HE-related hospitalizations, ED visits at 30 or 180 days, or mortality with 
vs. without a rifaximin order at discharge. 
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Chapter 1:  Introduction 
DISEASE OVERVIEW 
Introduction and Epidemiology 
Hepatic encephalopathy (HE) is a reversible complication of liver disease 
characterized by a spectrum of neuropsychiatric abnormalities ranging from mild cognitive 
impairment to life-threatening presentations, including coma. While HE poses a substantial 
burden to patients and caregivers, progress in treatment and prevention of the disease has 
been hindered by its complex pathogenesis.1 With mild cases often undiagnosed, the exact 
incidence of HE in the US is unknown and varies substantially based on the presence of 
risk factors. Within five years of diagnosis of cirrhosis, the risk for an initial episode of 
overt HE has been found to be between 5–25%,2-6 and patients with a previous episode of 
overt HE have a 40% cumulative risk for recurrence.7 Patients with transjugular 
intrahepatic portosystemic shunt (TIPS) are also at high risk of HE, with a median 
cumulative one-year incidence between 10–50%.8-9 The overall incidence of HE among 
Medicare enrollees with cirrhosis was found to be 11.6 per 100 patient-years.10 
Pathophysiology 
The etiology of HE is hypothesized to be multifactorial in nature, with excess 
presence of ammonia historically being considered as the main factor leading to HE. 
Ammonia is produced predominantly by colonic bacterial species with urease enzyme 
activity (e.g., Enterobacteriaceae, Proteus, and Clostridium species). Bacterial urease 
leads to the breakdown of urea in the bloodstream into ammonia and carbon dioxide.11 
Alternatively, enterocytes in the small bowel can also generate ammonia via intestinal 
glutaminase.12 In healthy patients, ammonia generated by bacteria and enterocytes travels 
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to the liver for metabolism following the urea cycle in zone 1, which is then excreted as 
urea by the kidneys.11 However, in patients with liver disease, metabolism by the liver can 
be reduced and compounded by the shunting of blood away from the liver.13 In patients 
with HE, significant correlations between plasma ammonia levels, cerebral ammonia 
metabolism and magnetic resonance spectroscopy (MRS) alterations in white matter have 
been observed.14 Several mechanisms for ammonia toxicity have been proposed, primarily 
focused on astrocytes in the brain. For instance, metabolism of ammonia to glutamine by 
astrocytes can lead to increased intracellular osmolarity and cerebral edema, resulting in 
neuronal dysfunction and the manifestation of HE-related symptoms.11 
In addition to ammonia, other molecules have also been implicated in the 
pathogenesis of HE. Neurosteroids (e.g., allopregnanolone) modulate gamma-
aminobutyric acid (GABA)-A receptors, in a similar manner as benzodiazepines, which 
can also lead to astrocyte swelling.11 Indole and oxindole, which have sedating properties, 
have also been implicated in the pathogenesis of HE.11 Additional mechanisms involving 
acetylcholinesterase (AChE), hyponatremia, mercaptans, short-chain fatty acids, false 
neurotransmitters, manganese, and GABA have also been identified.11 
Inflammation and infection (with systemic inflammatory response syndrome) have 
also been associated with HE. Increased levels of the pro-inflammatory cytokines tumor 
necrosis factor (TNF)-alpha, interleukin (IL)-6 and IL-1B have been found to act 
synergistically with ammonia in causing cerebral edema.15 
Clinical Presentation 
HE manifests in a wide spectrum of neurological and psychiatric abnormalities, 
ranging from subclinical alterations to coma.1 Minimal HE may only result in minor 
changes in attention, memory, movement, or vision.16 However, progression of HE can 
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lead to several psychiatric and neurological symptoms, such as personality changes, 
excessive daytime sleepiness, disorientation to time and space, inappropriate behavior, 
confusion, and coma.17-18 Asterixis, also known as a flapping tremor, is a commonly 
observed motor symptom in patients with HE, and is used in the International Society for 
Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus for classifying the 
episode as ‘overt’ or ‘covert’. Other motor symptoms include hypertonia, hyper-reflexia, 
positive Babinski sign, and extrapyramidal dysfunction. 
Prognosis and Burden of Illness 
HE is associated with poor health outcomes and high economic burden. Data 
analyzed from the US Nationwide Inpatient Sample (NIS) from 2005 to 2009 showed that 
the yearly mortality rate for patients hospitalized with HE ranged from 14.1 to 15.6%, and 
the average length of inpatient stay was 8.1 to 8.5 days.19 According to separate analysis 
of NIS data from 2004 to 2014, HE-related hospitalizations increased annually from 95,232 
in 2004 to 156,205 in 2014.20 Cost data was reported in the analysis for 55,485 
hospitalizations in 2014, with an unadjusted total cost of approximately $620 million total 
(or $11,174 per hospitalization) for the sample.20 
Impaired health-related quality of life (HRQoL) is also a major consequence of HE. 
In a sample of 160 patients presenting for liver transplantation, average HRQoL scores, as 
measured through the Short Form (SF)-36 questionnaire, decreased in the physical 
component summary (29.3 vs. 35.6, P=0.018) and mental component summary (44.0 vs. 




CLINICAL PRACTICE GUIDELINES 
Evaluation 
Guidelines from the American Association for the Study of Liver Diseases 
(AASLD) published in 2014 recommend that providers caring for patients with HE 
consider the nature of the underlying disease, timing, presence or absence of precipitating 
factors, and symptom severity. There are three types of underlying disease: ‘Type A’ 
(patients with acute liver failure), ‘Type B’ (patients with bypass shunts), and, most 
commonly, ‘Type C’ (patients with chronic liver disease).1 In patients with Type B or C, 
patterns of HE may be described as ‘minimal’ (exhibiting no outward signs or symptoms 
in a typical clinical setting), ‘episodic’ (occurring at intermittent periods with or without 
an identifiable precipitating factor), ‘recurrent’ (time intervals of six months or less), or 
‘persistent’ (ongoing deficit in neuropsychological functioning). 
Patients that present with clinically apparent HE are typically classified on a four-
point scale following the West Haven Criteria, also known as the Conn Score.1 Guidelines 
recommend that every case be described and classified according to all four factors and 
repeated at relevant intervals. Classification based on West Haven Criteria is described in 












No encephalopathy or history of 
HE 




Alterations of tests exploring 
psychomotor speed, executive 
functions, or neurophysiological 
alterations without clinical 
evidence of mental change 





Trivial lack of awareness, 
euphoria or anxiety, shortened 
attention span, impairment of 
addition or subtraction, or altered 
sleep rhythm 
Oriented in time and 
space, but some 
cognitive or behavior 




Lethargy or apathy, disorientation 
for time, obvious personality 
change, inappropriate behavior, 
dyspraxia, asterixis 
Disoriented for time ± 
the other mentioned 
symptoms 
Grade III 
Somnolence to semistupor, 
responsive to stimuli, confused, 
gross disorientation, bizarre 
behavior 
Disoriented also for 
space ± the other 
mentioned symptoms 
Grade IV Coma 
Does not respond even 
to painful stimuli 
Table 1.1: West Haven Criteria and Clinical Description [Adapted]1 
For patients with liver disease, prognostic models have been utilized to estimate 
mortality for prioritization of organ allocation for transplantation. The Model for End-stage 
Liver Disease (MELD) score is a validated system for chronic liver disease severity 
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scoring.22 It was originally developed to predict three-month mortality following TIPS 
placement,23 but has been used for all patients with chronic liver disease given its strength 
in predicting survival and mortality. The score includes three laboratory values: serum 
bilirubin [mg/dL], international normalized ratio (INR), and serum creatinine (SCr) 
[mg/dL]. Scores typically range from 6 to 40, with large increases commonly seen during 
periods of infection or acute decompensation. Mortality rates at three months for patients 
with chronic liver disease by MELD scores are summarized in Table 1.2 below: 
 
MELD Score* 3-month Mortality Rate 
<9 1.9% 
10 to 19 6.0% 
20 to 29 19.6% 
30 to 39 52.6% 
>40 71.3% 
* MELD = 3.8*ln(bilirubin) + 11.2*ln(INR) + 9.6*ln(SCr) + 6.4 
Table 1.2: 3-month Mortality Rates by MELD Score24 
Treatments 
Patients with a history of overt HE are at high risk of recurrent episodes. Several 
strategies are recommended to prevent recurrent episodes of HE, including control of 
precipitating factors, nutritional support, and pharmacologic therapies to lower blood 
ammonia, specifically nonabsorbable disaccharides (e. g. lactulose) and rifaximin.1 
Nonabsorbable Disaccharides 
Lactulose (brand: Constulose®, Enulose®, Generlac®, Kristalose®) is indicated for 
the prevention and treatment of portal-systemic encephalopathy25 and is considered first-
line for the treatment and prevention of overt HE.1 Upon oral administration, it is degraded 




thereby inhibiting diffusion of ammonia into the bloodstream. Lactulose also enhances the 
diffusion of NH3 from the blood into the gut, where it is again converted to NH4
+. 
Additionally, lactulose produces an osmotic effect in the colon, and is commonly used for 
the treatment of constipation. 
For HE prophylaxis, 30 to 45 mL of lactulose is administered between three to four 
times per day, titrated to achieve two to three soft stools per day. In an open-label trial of 
patients with cirrhosis who recovered from a previous episode of HE (N=140), 12 of 61 
(19.6%) patients treated with lactulose experienced a subsequent HE, compared to 30 of 
64 (46.8%) who were not treated with lactulose (P=0.001).7 Adverse effects of lactulose 
reported in the study were diarrhea (23%), bad taste (13%), and abdominal bloating (10%). 
Additionally, lactulose can cause dehydration, electrolyte imbalances, nausea, vomiting, 
flatulence, and abdominal cramps/distress. 
Lactulose is available in the US by prescription only at a relatively low cost. As of 
October 2020, the average wholesale price (AWP) for a 473 mL package size of lactulose 
is $34.70 to $40.15, which corresponds to an AWP per 30-day supply of $198 to $458, 
depending on the prescribed dose and frequency of use.26 
Rifaximin 
Rifaximin (brand: Xifaxan®) is an antibiotic indicated to reduce the risk of overt 
HE recurrence in adults.27 Its mechanism of action occurs through binding to the beta-
subunit of bacterial DNA-dependent RNA polymerase, thereby inhibiting bacterial protein 
synthesis. It has a broad spectrum of activity against gram-positive and gram negative, 
aerobic and anaerobic, enteric bacteria, and poorly absorbed, with 97% excretion through 
feces unchanged. Additionally, rifaximin is indicated for the treatment of travelers’ 
diarrhea (TD) and irritable bowel syndrome with diarrhea (IBS-D). 
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Efficacy for rifaximin was established in a randomized, double-blind, placebo-
controlled trial (Bass et al., 2010)28 of patients with at least two prior episodes of HE 
associated with chronic liver disease in the previous six months but were in remission 
(Conn score of 0 or 1) at baseline. Patients (mean age 56 years, age range 21–82 years, 
61% male, 86% white) included in the study (N=299) were randomized to receive rifaximin 
550 mg twice daily (n=140), or placebo (n=159). Lactulose was used concomitantly in 91% 
of patients. MELD scores at baseline were between 11–18 for 64% of patients, and no 
patients had a MELD score >25. Breakthrough overt HE episodes, defined as an increase 
of Conn score ≥2, occurred in 31 (22%) patients that received rifaximin compared to 73 
(46%) patients that received placebo during the six-month study period (P<0.0001). HE-
related hospitalizations, defined as hospitalizations directly resulting from HE or 
hospitalizations complicated by HE, occurred in 19 (14%) of patients receiving rifaximin 
compared to 36 (23%) patients receiving placebo (P=0.0129). Adverse events occurring at 
over 5% and at a higher rate in the rifaximin vs. placebo group included peripheral edema 
(15% vs. 8%), dizziness (13% vs. 8%), pruritus (9% vs. 6%), anemia (8% vs. 4%), 
arthralgia and pyrexia (6% vs. 3%, each). Death occurred in 9 (6.4%) patients in the 
rifaximin group and 11 (6.9%) in the placebo group. 
The AWP of rifaximin 550 mg is $3,066.71 for 60 capsules (30-day supply), 
considerably higher than for a 30-day supply of lactulose. However, there are studies 
demonstrating cost-effectiveness of rifaximin compared to lactulose, which are described 
in more detail later in this chapter.29 
Follow-up 
Upon discharge from a hospital admission, guidelines recommend that the medical 
team confirm neurological status, recognize precipitating factors, and provide discharge 
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consultation to prevent reappearance of precipitating factors.1 Education of patients, 
relatives and caregivers is essential for prevention, and should consist of medication 
effects, importance of adherence, signs of recurrent HE, and actions to be taken in case of 
recurrence.1 Underlying liver pathology in some patients can improve with time and 
nutrition, though most patients with a previous overt HE episode have advanced liver 
failure that will not result in functional improvement.1 Adequate intake of protein to 
increase muscle mass is recommended, as weight loss with sarcopenia may worsen HE.1 
 
LITERATURE REVIEW ON THE USE OF RIFAXIMIN AS PROPHYLAXIS FOR HEPATIC 
ENCEPHALOPATHY 
Observational Studies 
Hammond et al. (2017)30 conducted a retrospective cohort study using a 10% 
random sample of medical and pharmacy claims from the IMS LifeLink PharMetrics Plus 
database between January 2006 and June 2015 (N=606). Patients were divided into two 
treatment groups – lactulose plus rifaximin (n=169) vs. lactulose only (n=437) – and 
followed for six months following an initial overt HE event. No difference in 
hospitalization for HE was observed between treatment groups (16.0% vs. 15.3%, 
P=0.841). Further adjustment for confounders also did not show a statistically significant 
difference in risk for an overt HE event (HR: 1.05, 95% CI [0.81, 1.28]). Of note, results 
are only available in abstract, and the authors acknowledge that findings may be due to 
residual, unobserved confounding. 
Courson et al. (2015)31 retrospectively reviewed electronic health record (EHR) 
data in hospitalized patients admitted for HE to a single hospital in Tennessee between 
2007 and 2012. Of the entire study population (N=173), 110 patients were eligible for 
 
 10 
analysis of hospital readmission rates. Patients were grouped by treatment received while 
in the hospital – lactulose only (n=68), lactulose plus rifaximin (n=42). Of note, two 
patients (2.9%) in the lactulose only group were discharged with a prescription for 
rifaximin compared to 25 (59.5%) in the lactulose plus rifaximin group. HE-related 
admissions observed at 180 days were significantly lower in patients in the lactulose plus 
rifaximin group (n=1, 2.4%) compared to lactulose monotherapy (n=11, 16.2%, P=0.028). 
However, there were no statistically significant differences found in HE-related 
readmissions at 30 days, and all-cause readmissions at 30 and 180 days. 
Vadhariya et al. (2020)32 conducted a retrospective analysis of claims data in 
Medicare patients in Texas who were hospitalized and recovered from HE from January 
2011 to May 2018 (N=184). Overall, medication use at discharge was identified in 117 
(63.5%) patients, with only 9 (4.9%) receiving rifaximin. Adherence rates, measured 
through proportion of days covered (PDC), were relatively low in this population, ranging 
from 0.56 to 0.82 at three months and 0.48 to 0.77 at six months. 
Hudson et al. (2017)33 conducted a retrospective, cross-sectional study in patients 
with HE that received care at multiple hospitals across the UK between July 2008 and May 
2014 (N=114). Statistically significant reductions in the mean number of liver-related and 
all-cause hospitalizations were observed in the six months following initiation of rifaximin, 
compared to the previous six months (liver-related: 1.3 vs. 0.5, P<0.001; all-cause: 1.9 vs. 
0.9, P<0.001). Similar reductions in the mean numbers of hospital bed days, 30-day 
hospital readmissions, and emergency department (ED) visits were also observed. 
Kang et al. (2017)34 evaluated patients at a single tertiary hospital in South Korea 
who recovered from HE between January 2010 and June 2015 (N=1,042). In patients 
without hepatocellular carcinoma (HCC), those who received rifaximin plus lactulose 
(n=145) had a significantly lower risk of recurrent HE (HR: 0.452, P=0.001) and death 
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(HR: 0.697, P=0.24) compared to patients that only received lactulose (n=276). However, 
there was not a statistically significant difference between treatment groups in the rate of 
recurrent HE in patients with HCC (HR: 0.689, P=0.57). 
Pharmacoeconomic Analysis 
Jesudian et al. (2020)35 assessed the incremental cost-effectiveness of rifaximin 
(with and without lactulose) compared to control (also, with and without lactulose) in 
patients with HE. Costs and outcomes were evaluated using a Markov model. The model 
predicted the course of HE upon initiation of maintenance therapy to avoid recurrent HE 
episodes over a lifetime horizon. Four health states were modeled, as shown in Figure 1.1: 
(1) remission, (2) overt HE (with or without hospitalization), (3) transplant, and (4) death. 
Patients start in remission and are eligible to transition to each of the different health states 
every two weeks. Liver transplantation and death are both considered to be exit states. 
 
 
Figure 1.1: Cost-effectiveness Model Structure [Adapted]35 
Inputs for the cost-effectiveness model are summarized in Table 1.3. Data sources 
for the clinical modeling inputs include the 6-month pivotal clinical trial (Bass et al., 
201028), the 24-month open-label maintenance study (Mullen et al., 201436), and a 
randomized controlled trial of hospitalized patients (Sharma et al., 201337). HE-related 
Remission 





health utilities were estimated using interviewer-administered time trade-off and standard 
gamble utilities from a random sample of subjects in the UK (Guest et al., 201438). 
Hospitalization costs were estimated from several data sources and adjusted to 2018 US 
dollars. 
 
Input Rifaximin Control Source 
On concomitant lactulose 91.4% 91.2% Bass et al., 201028 
Remission state 
With overt episodes at 6 months 22.1% 45.9% Bass et al., 201028 
Hospitalizations per person-years 0.24 0.58 Mullen et al., 201436 
Mortality at year 5 52.8% 59.9% Mullen et al., 201436 
Health utility 0.937 Guest et al., 201438 
Overt HE state 
Hospitalized 61.5% 49.2% Bass et al., 201028 
Reversed after 2 weeks (hospital) 76.0% 44.0% Sharma et al., 201337 
Mortality after 2 weeks (in-hospital) 23.8% 49.1% Sharma et al., 201337 
Mortality after 2 weeks (post-
hospital) 
0.6% 0.9% Mullen et al., 201436 
Mortality after 2 weeks (non-
hospital) 
0.6% 0.9% Mullen et al., 201436 
Health utility 0.783 Bass et al., 2010,28 
Guest et al., 201438 
Transplant state 
Transplants per patient per year 0.061 Mullen et al., 201436 
Life expectancy after transplant 29.3 year Kim et al., 201839 
Health utility 0.962 Guest et al., 201438 
Costs 
HE-related hospitalization $19,710 $24,527 Multiple 
Non-HE-related hospitalization $15,892 Multiple 
Liver transplantation $183,132 Multiple 
Table 1.3: Cost-Effectiveness Model Inputs [Adapted]35 
The model estimated 6.4 quality-adjusted life years (QALY) per patient receiving 
rifaximin at a total cost of $152,406, compared to 3.1 QALYs per patient in the control 
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group at a total cost of $56,031. As such, the incremental cost per QALY from the addition 




Bass et al. (2008)28 demonstrated that rifaximin was substantially superior to 
lactulose for the prevention of recurrent HE-related hospitalizations; however, there is 
limited evidence confirming the real-world effectiveness of rifaximin as prophylaxis. In a 
recent literature review on evidence of long-term management of HE with lactulose and/or 
rifaximin,40 the authors discussed the limited availability of direct head-to-head evidence 
to support rifaximin over lactulose. In addition to the lack of effectiveness observed in 
Hammond et al. (2017),30 conflicting evidence in the efficacy of rifaximin as observed in 
a single-center, randomized controlled trial41 has also raised speculation of different 
outcomes occurring in patients with an etiology of cirrhosis, or different geographical and 
dietary backgrounds.40  
Decreases in direct costs due to HE-related hospital admissions and ED visits are 
needed to offset the high drug cost of rifaximin relative to lactulose. While cost-
effectiveness has been demonstrated using inputs sourced from clinical trials, application 
of real-world evidence to economic analyses remains limited. 
Purpose 
This study assesses the real-world effectiveness of rifaximin as prophylaxis for HE 
using electronic health record (EHR) data at Baylor Scott & White Health (BSWH), a large 
integrated health system in Central and North Texas. BSWH is comprised of 52 hospitals 
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and over 800 patient access points, with more than 7.5 million patient encounters, 900,000 
ED visits, and 200,000 hospital admissions occurring at BSWH, annually.42 Results from 
this analysis can be used to better inform existing cost-effectiveness models. The methods 







Chapter 2:  Methods 
OBJECTIVES AND HYPOTHESES 
The aim of the study was to evaluate the effectiveness of rifaximin used as 
prophylaxis for hepatic encephalopathy (HE) at BSWH. Effectiveness was measured 
through healthcare utilization metrics related to hospitalizations and emergency 
department (ED) visits. The full list of objectives and hypotheses are summarized in Table 
2.1 below: 
 
Objective 1: To evaluate the baseline characteristics of patients following the first 
qualifying episode of HE. 
• H0 1.1: The difference in patient age between treatment groups is not statistically 
significant. 
• H0 1.2: The difference in proportions of patients by age category between treatment 
groups is not statistically significant. 
• H0 1.3: The difference in proportions of patients by gender between treatment 
groups is not statistically significant. 
• H0 1.4: The difference in proportions of patients by race category between treatment 
groups is not statistically significant. 
• H0 1.5: The difference in proportions of patients by ethnicity between treatment 
groups is not statistically significant. 
• H0 1.6: The difference in proportions of patients by primary insurance type between 
treatment groups is not statistically significant. 
• H0 1.7: The differences in proportions of patients with select comorbiditiesi at 
baseline between treatment groups are not statistically significant. 
• H0 1.8: The difference in patient comorbidity index between treatment groups is not 
statistically significant. 
• H0 1.9: The differences in individual laboratory measurementsii at baseline between 
treatment groups are not statistically significant. 
• H0 1.10: The difference in proportions of patients by MELD score categoryiii at 
baseline between treatment groups is not statistically significant. 
• H0 1.11: The difference in proportions of patients by Glasgow Coma Scale 
categoryiv at baseline between treatment groups is not statistically significant. 
• H0 1.12: The difference in proportions of patients by prior medication usev between 
treatment groups is not statistically significant. 
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• H0 1.13: The difference in length of stay at baseline between treatment groups is not 
statistically significant. 
• H0 1.14: The difference in proportion of patients with active lactulose orders at 
baseline between treatment groups is not statistically significant. 
i Comorbidities = cirrhosis, hepatocellular carcinoma, hepatitis B, hepatitis C, non-alcoholic fatty liver 
disease (NAFLD), alcohol abuse, diabetes, and renal failure 
ii Laboratory measurements = SCr, bilirubin, INR, serum aminotransferase levels (e.g. AST, ALT), 
ammonia, and white blood cell count (WBC). WBC was categorized as elevated (>11,000 cells per μl of 
blood, or not elevated). 
iii MELD score values were categorized as ≤5, 6–10, 11–15, 16–20, 21–25, 26–30, or ≥31 
iv Glasgow Coma Scale values were categorized as mild (13–15), moderate (9–12), and severe (3–8) 
v Prior medications = rifaximin, lactulose 
 
Objective 2: To compare healthcare utilization metrics in patients that did or did 
not receive rifaximin following the first qualifying episode of HE. 
• H0 2.1: The difference in proportions of patients with at least one all-cause 
hospitalization at 180 days between treatment groups is not statistically significant. 
• H0 2.2: The difference in proportions of patients with at least one liver-related 
hospitalization at 180 days between treatment groups is not statistically significant. 
• H0 2.3: The difference in proportions of patients with at least one HE-related 
hospitalization at 180 days between treatment groups is not statistically significant. 
• H0 2.4: The difference in proportions of patients with at least one all-cause 
hospitalization at 30 days between treatment groups is not statistically significant. 
• H0 2.5: The difference in proportions of patients with at least one liver-related 
hospitalization at 30 days between treatment groups is not statistically significant. 
• H0 2.6: The difference in proportions of patients with at least one HE-related 
hospitalization at 30 days between treatment groups is not statistically significant. 
• H0 2.7: The difference in proportions of patients with at least one all-cause ED visit 
at 180 days between treatment groups is not statistically significant. 
• H0 2.8: The difference in proportions of patients with at least one liver-related ED 
visit at 180 days between treatment groups is not statistically significant. 
• H0 2.9: The difference in proportions of patients with at least one HE-related ED 
visit at 180 days between treatment groups is not statistically significant. 
• H0 2.10: The difference in proportions of patients with at least one all-cause ED visit 
at 30 days between treatment groups is not statistically significant. 
• H0 2.11: The difference in proportions of patients with at least one liver-related ED 
visit at 30 days between treatment groups is not statistically significant. 
• H0 2.12: The difference in proportions of patients with at least one HE-related ED 
visit at 30 days between treatment groups is not statistically significant. 
• H0 2.13: The difference in time to first all-cause hospitalization between treatment 
groups is not statistically significant. 
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• H0 2.14: The difference in time to first liver-related hospitalization between 
treatment groups is not statistically significant. 
• H0 2.15: The difference in time to first HE-related hospitalization between treatment 
groups is not statistically significant. 
• H0 2.16: The difference in time to first all-cause ED visit between treatment groups 
is not statistically significant. 
• H0 2.17: The difference in time to first liver-related ED visit between treatment 
groups is not statistically significant. 
• H0 2.18: The difference in time to first HE-related ED-visit between treatment 
groups is not statistically significant. 
 
Objective 3: To assess the accuracy of using EHR data to define medication use in 
patients prescribed rifaximin as prophylaxis for HE. 
• H0 3.1: The difference in proportions of patients with rifaximin ordered vs. filled 
data is not statistically significant. 
• H0 3.2: The difference in proportions of patients with rifaximin ordered vs. 
proportion of days covered by rifaximin ≥80% is not statistically significant. 






The study followed an observational, retrospective, cohort design, utilizing existing 
data from the electronic health record (EHR) at BSWH. The study was approved by the 
Institutional Review Boards at BSWH (expedited review) and the University of Texas at 
Austin (exempt). 
As shown in Figure 2.1, data were collected during the study period from January 
1, 2014 to Dec 31, 2020. A baseline period of 6 months was used to ensure no prior recent 
history of HE-related hospitalizations. Patients were then followed for 6 months post-index 






Figure 2.1: Study Design  
 
POPULATION 
Patients were enrolled into the study on the index date, defined as the discharge 
date from the first eligible HE-related hospitalization during the enrollment period. 
Eligibility criteria for HE-related hospitalizations were defined through several inclusion 
and exclusion criteria as described in Table 2.2 below:  
 
  
 Jan 1, 2014   Jul 1, 2014  Jul 4, 2020   Dec 31, 2020 
Baseline Enrollment  Follow-up 
Period Period   Period 
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Inclusion Criteria Exclusion Criteria 
• Discharged from an HE-related 
hospitalization during the study 
enrollment period to home (with 
home health, or self-care) or an 
assisted living facility (long term 
acute care, nursing facility, rehab 
facility, skilled nursing facility or 
custodial care facility) 
• Age ≥18 years at index date 
• Sufficient laboratory data during 
the first eligible HE-related 
hospitalization to calculate a 
MELD score (e.g. SCr, bilirubin, 
and INR)   
 
• No HE-related hospitalizations during 
the 6 months prior to the index date 
• Admitted to transplant or hospice 
service for first episode of HE 
• Discharged from the first episode of HE 
with planned inpatient acute care 
readmission, discharged to another 
hospital, hospice, court/law 
enforcement, or left against medical 
advice 
• Deceased during the first episode of HE 
• Patients with insufficient laboratory 
results needed to calculate a MELD 
score during the first eligible HE-related 
hospitalization 
Table 2.2: Study Criteria 
Hospitalizations were considered to be HE-related if a diagnosis of HE (identified 
using ICD-9-CM and ICD-10-CM codes listed in Appendix A) was coded in any position 
or noted as the primary problem. A sensitivity analysis was conducted using different 
requirements for the position of the HE-related diagnosis code (e.g. all positions, first eight 
positions, first four positions, primary and secondary positions, or primary position only). 
Criteria related to discharge disposition was intended to capture patients that might receive 
the most benefit from prophylaxis with rifaximin. Patients were also required to have 
laboratory data (SCr, biliriubin, and INR) from the first HE-related hospitalization for 





Eligible patients were grouped based on the presence or absence of an active, 
outpatient medication order for rifaximin at discharge. However, medication orders are 
prescribing events that do not necessarily correlate with the prescribed medication being 
taken or even filled by the patient. In comparison, medication fills, which can be identified 
using pharmacy (Rx) claims data, allow for calculation of a proportion of days covered 
(PDC) ratio, which can more closely approximate medication use. An exploratory analysis 
was conducted on the subset of study patients enrolled in the Scott & White Health Plan 









Figure 2.2: Available Methods for Assessing Medication Use in Retrospective Studies 
 
DATA COLLECTION 
Data were extracted from the BSWH EHR using EPIC Caboodle data model. Rx 
claims data for study patients continuously enrolled in the SWHP during the study period 
was extracted from the Virtual Data Warehouse (VDW). A full list of variables extracted 





Medication Orders / List Medication Fills Medication Use 
EHR  Rx Claims 


















Cirrhosis (all) • Active on the patient’s 
problem list during the first 
eligible HE-related 
hospitalization, or an 
outpatient encounter with a 
date between the 6-month 










Additional comorbidities for 




Serum creatinine (last) • Measured during the 
qualifying episode of HE Bilirubin (last) 
INR (last) 
AST serum level (last) 
ALT serum level (last) 
Ammonia (first) 
White blood cell count (first) 




Medication name • Order date between the 6-
month pre-index date and 








Encounter key • During the entire study 
period (eligibility) 
• Between the index date and 




Diagnosis sequence number 
Discharge date 
Discharge disposition 




ED Visits  
(EPIC Caboodle) 
Encounter key Between the index date and 6 
months post-index Encounter date 
Chief complaint 
Coded diagnosis 
Diagnosis position number 
Mortality 
(EPIC Caboodle) 
Identifier Death date prior to the 6-
month post-index date Death date 
Pharmacy claims 
(VDW) 
Patient identifier Date of service between the 6-
months pre-index date and 6-
months post-index date 
Medication name 
Date of service 
Quantity 
Day supply 
Table 2.3: Study Variables 
Patient characteristics including age, sex, race, ethnicity, and primary insurance 
type were collected at baseline. Patients with race recorded as ‘American Indian or Alaska 
Native’, ‘Asian’, ‘Native Hawaiian or Other Pacific Islander’, ‘Puerto Rican’, ‘Other’, and 
‘Some Other Race Only’ were all re-categorized as ‘Other’ due to low sample sizes. 
Comorbidities were identified by searching for EHR diagnosis keys that map to ICD-9-
CM or ICD-10-CM diagnosis codes (as detailed in Appendix A) that were either coded 
during the first eligible HE-related encounter, or active on the patient’s problem list during 
an outpatient encounter between the 6-month pre-index date and the index date. 
Additionally, an Elixhauser Comorbidity Index (ECI) was calculated for each patient using 
Elixhauser Comorbidity Software, Version 3.7 from the Healthcare Cost and Utilization 
Project (HCUP).43  
Laboratory data from the first eligible HE-related encounter were also collected to 
describe and characterize patients’ disease severity at baseline. The last measurement in 
the encounter was used for each of the components of the MELD score (SCr, bilirubin, and 
INR), whereas the first measurement in the encounter was used for ammonia and WBC 
count. MELD scores were then calculated for each patient at baseline. Additionally, a 
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cutoff of >11,000 cells per μl of blood was used to define categorize WBC values as 
elevated or not elevated. The first measurement of the Glasgow Coma Scale scaled score 
during the first eligible HE-related encounter was collected from flowsheet data. Lastly, 
length of stay (LOS) of the first eligible HE-related encounter was reported in days. 
OUTCOME MEASURES 
The primary effectiveness outcome measure for the study was the proportion of 
patients with at least one hospital admission during the post-index study period by 
treatment group (rifaximin vs. no rifaximin). Hospital admissions were categorized by 
coded diagnoses as being HE-related, liver-related, and/or all-cause, with a sensitivity 
analysis performed based on the positioning of the diagnosis code used to define a 
hospitalization as HE- or liver-related. Outcomes occurring within 30 days and/or 180 days 
post-index were assessed. Time (in days) to first hospital admission was also collected and 
reported separately based on the reason for admission (all-cause, liver-related, HE-related).  
As a secondary outcome measure, emergency department (ED) visits were 
collected and reported in a similar manner as hospital admissions. Coded diagnoses were 
used to categorize ED visits as HE-related, liver-related and/or all-cause. Results were 
reported as proportions of patients with at least one ED visit in each of the respective 
categories (all-cause, liver-related, HE-related) and time periods (30 days, 180 days). 
All-cause mortality data was also collected from the EHR and reported as an 
outcome measure. Counts and proportions of patients that died during the 180 days post-
index were reported, along with a survival analysis. 
Two exploratory endpoints were used to measure rifaximin medication fills from 
pharmacy claims data in the subset of study patients with SWHP insurance coverage: (1) 
the proportion of study patients with a claim for rifaximin during the study period; and (2) 
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the proportion of patients with PDC ≥80% by rifaximin. For PDC calculations, the index 
date was used as the start date, and either the 6-month post-index date or the date of the 




Using results from Bass et al. (2010),28 a power analysis was conducted with 
G*Power software, Version 3.1 to estimate the number of patients needed for detection of 
the primary outcome measure. Assuming a 1:1 treatment allocation, a total sample size of 
452 patients was calculated in order to achieve 80% power with an alpha of 0.05. 
Propensity Score Matching 
To emulate the properties of a randomized experiment, a cohort of patients matched 
to each treatment group based on propensity scores (PS) was created, ensuring similar 
distributions of covariates across treatment groups. To identify which characteristics to 
include as covariates in the PS-model, a directed acyclic graph was developed using 
DAGitty Software, Version 3.0.44 Figure 2.3 shows causal relationships between rifaximin 
(green node with triangle), the primary outcome measure (blue node), controlled covariates 





Figure 2.3: Directed Acyclic Graph for Causal Pathways of HE-related Re-hospitalization 
While risk factors in the directed acyclic graph such as alcohol abuse, underlying 
liver disease, renal dysfunction and infection could be measured and controlled for, several 
other factors such as medications that affect the central nervous system (CNS), poor diet, 
and other potential triggers are not measured and controlled for, serving as possible 
confounders in this study. Additionally, adherence to rifaximin was not observable in this 
study due to the limitations of EHR data. 
PS were estimated through logistic multivariable regression using the following list 
of covariates: age, age category, gender, insurance type, cirrhosis (any), cirrhosis 
(alcoholic), hepatocellular carcinoma (HCC), hepatitis B, hepatitis C, NAFLD, alcohol 
abuse, diabetes, renal failure, Elixhauser Comorbidity Index, MELD score, MELD 
category, Glasgow Coma Scale category, length of stay of the baseline encounter, and 





Descriptive statistics (mean, standard deviation (SD), median, interquartile range 
(IQR), number of observations (n) and proportions) were used to summarize patient and 
clinical characteristics at baseline. Inferential statistical tests matched to each study 
objective and hypothesis are listed in Table 2.4:  
 
H0 Variable Type Statistical Test 
1.1 Age Continuous T-test 
1.2 Age category: ≥65 years Dichotomous Chi-Square 
1.3 Gender Dichotomous Chi-Square 
1.4 Race Categorical Chi-Square 
1.5 Ethnicity Categorical Chi-Square 
1.6 Primary Insurance Categorical Chi-Square 
1.7a Comorbidity: Cirrhosis (all) Dichotomous Chi-Square 
1.7b Comorbidity: Cirrhosis (alcoholic) Dichotomous Chi-Square 
1.7c Comorbidity: Hepatocellular Carcinoma Dichotomous Chi-Square 
1.7d Comorbidity: Hepatitis B Dichotomous Chi-Square 
1.7e Comorbidity: Hepatitis C Dichotomous Chi-Square 
1.7f Comorbidity: NAFLD Dichotomous Chi-Square 
1.7g Comorbidity: Alcohol Abuse Dichotomous Chi-Square 
1.7h Comorbidity: Diabetes Dichotomous Chi-Square 
1.7i Comorbidity: Renal Failure Dichotomous Chi-Square 
1.8 Elixhauser Comorbidity Index Ordinal Mann Whitney 
1.9a Lab: SCr Continuous Mann Whitney 
1.9b Lab: Bilirubin Continuous Mann Whitney 
1.9c Lab: INR Continuous Mann Whitney 
1.9d Lab: Ammonia Continuous Mann Whitney 
1.9e Lab: Elevated WBC Dichotomous Chi-Square 
1.10 MELD score category Dichotomous Chi-Square 
1.11 Glasgow Coma Scale category Dichotomous Chi-Square 
1.12a Prior Medications: Lactulose Dichotomous Chi-Square 
1.12b Prior Medications: Rifaximin Dichotomous Chi-Square 
1.13 Baseline Admit: Length of Stay Ordinal Mann Whitney 
1.14 Baseline Admit: Lactulose at Discharge Dichotomous Chi-Square 
2.1 ≥1 all-cause hospitalization at 180 days Dichotomous Chi-Square 
2.2 ≥1 liver-related hospitalization at 180 days Dichotomous Chi-Square 
2.3 ≥1 HE-related hospitalization at 180 days Dichotomous Chi-Square 
2.4 ≥1 all-cause hospitalization at 30 days Dichotomous Chi-Square 
2.5 ≥1 liver-related hospitalization at 30 days Dichotomous Chi-Square 
2.6 ≥1 HE-related hospitalization at 30 days Dichotomous Chi-Square 
2.7 ≥1 all-cause ED visit at 180 days Dichotomous Chi-Square 
2.8 ≥1 liver-related ED visit at 180 days Dichotomous Chi-Square 
2.9 ≥1 HE-related ED visit at 180 days Dichotomous Chi-Square 
2.10 ≥1 all-cause ED visit at 30 days Dichotomous Chi-Square 
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H0 Variable Type Statistical Test 
2.11 ≥1 liver-related ED visit at 30 days Dichotomous Chi-Square 
2.12 ≥1 HE-related ED visit at 30 days Dichotomous Chi-Square 
2.13 Days to first all-cause hospitalization Ordinal Cox Regression / K-M curves 
2.14 Days to first liver-related hospitalization Ordinal Cox Regression / K-M curves 
2.15 Days to first HE-related hospitalization Ordinal Cox Regression / K-M curves 
2.16 Days to first all-cause ED visit Ordinal Cox Regression / K-M curves 
2.17 Days to first liver-related ED visit Ordinal Cox Regression / K-M curves 
2.18 Days to first HE-related ED visit Ordinal Cox Regression / K-M curves 
3.1 Rifaximin orders vs fills Dichotomous Cohen’s Kappa 
3.2 Rifaximin orders vs. PDC ≥80% Dichotomous Cohen’s Kappa 
Table 2.4. Summary of Hypotheses and Statistical Tests 
For analyses of both the full, unmatched cohort and the PS-matched cohort, 
independent t-tests were used for comparison of means between treatment groups, Mann 
Whitney U tests were performed for ordinal or continuous but non-normally distributed 
data, and Chi-square tests were used for proportional comparisons. Baseline characteristics 
(Objective 1) were evaluated for similarity with α=0.2, whereas differences in outcome 
measures (Objective 2) were assessed with α=0.05. Cox proportional hazards models and 
Kaplan Meier (K-M) curves were used for time-to-event analyses. Lastly, an agreement 
analysis was conducted for comparison of medication fill measures from pharmacy claims 
data with treatment group assignments from EHR data. Results for this analysis were 
summarized descriptively using a frequency table, and level of agreement was assessed 




Chapter 3:  Results 
STUDY SAMPLE 
A total of 1,541 patients met all study criteria, as shown in Figure 3.1 below: 
 
 
Figure 3.1. Selection Flow Chart 
N=261 patients excluded due to missing lab value(s) for MELD score 
 N=253, missing INR 
 N=30, missing total bilirubin (T.bili) 
 N=5, missing serum creatinine (SCr) 
 
N=77 patients excluded due to history of HE-related hospitalization 
at BSWH during the baseline study period (1/1/2014 – 7/1/2014) 
N=8 patients excluded due to age <18 years at baseline or unknown 
N=2,747 unique patients with at least one HE-related hospitalization at a Baylor 
Scott & White Health (BSWH) facility during the study period 
N=805 patients excluded due to discharge disposition 
 N=351, deceased 
 N=267, hospice 
 N=117, discharged to another hospital 
 N=44, left against medical advice 
 N=26, court/law enforcement   
N=1,942 patients discharged to 
home or long-term care facility 
N=1,934 patients age ≥18 years  
N=1,673 patients with lab values 
for MELD score calculation 
N=1,596 patients with no HE-related hospitalizations at 
BSWH in the previous 6 months 
N=1,541 patients meeting all inclusion and exclusion study criteria 
N=55 patients excluded due to admission to transplant or 
hospice service during the first HE-related hospitalization 
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Overall, 2,747 patients with at least one HE-related hospitalization at BSWH during 
the study period were identified using data from the electronic health record (EHR). Each 
of the study criteria were applied resulting in exclusion of patients due to discharge 
disposition (N=805, 29%), missing laboratory values for MELD score calculation (N=261, 
10%), history of HE-related hospitalization at BSWH during the baseline study period 
(N=77, 3%), admission to transplant or hospice service during the first HE-related 
hospitalization (N=55, 2%), and age less than 18 years (N=8, <1%). The majority of 
patients excluded due to discharge disposition were deceased (N=351, 44%) or hospice 
(N=267, 33%), and INR was the most common MELD laboratory value that was missing 
(N=253, 97%). 
Patients were grouped based on the presence (N=351, ‘Rifaximin’) or absence 
(N=1,191, ‘Control’) of an active order for rifaximin documented in the EHR at baseline. 
Application of the PS-matching methods described in Chapter 2 yielded 347 matched pairs 
in each treatment group (N=694, total). 
 
BASELINE CHARACTERISTICS 
Patient characteristics are summarized by treatment group for both the full study 

















Age, mean (SD) 60.00 (11.25) 60.27 (12.20) 0.6975 60.19 (11.32) 59.75 (11.78) 0.6176 
Age category, N (%)   0.4131   0.9363 
< 65 years 260 (66.67%) 741 (64.38%)  228 (65.71%) 227 (65.42%)  
≥ 65 years 130 (33.33%) 410 (35.62%)  119 (34.29%) 120 (34.58%)  
Gender, N (%)   0.4392   0.8196 
Female 185 (47.44%) 520 (45.18%)  167 (48.13%) 164 (47.26%)  
Male 205 (52.56%) 631 (54.82%)  180 (51.87%) 183 (52.74%)  
Race, N (%)   0.8164   0.8587 
White or Caucasian 320 (82.05%) 949 (82.45%)  288 (83.00%) 284 (81.84%)  
Black or African American 37 (9.49%) 119 (10.34%)  30 (8.65%) 34 (9.80%)  
Other 27 (6.92%) 70 (6.08%)  23 (6.63%) 25 (7.20%)  
Unknown 6 (1.54%) 13 (1.13%)  6 (1.73%) 4 (1.15%)  
Ethnicity, N (%)   0.4727   0.1582 
Hispanic or Latinx 80 (20.51%) 265 (23.02%)  74 (21.33%) 86 (24.78%)  
Not Hispanic or Latinx 305 (78.21%) 876 (76.11%)  268 (77.23%) 260 (74.93%)  
Unknown 5 (1.28%) 10 (0.87%)  5 (1.44%) 1 (0.29%)  
Patient Insurance Type, N (%)   0.2215   0.9450 
Commercial 92 (23.59%) 255 (22.15%)  82 (23.63%) 80 (23.05%)  
Medicare 195 (50.00%) 556 (48.31%)  175 (50.43%) 174 (50.14%)  
Medicaid 44 (11.28%) 123 (10.69%)  38 (10.95%) 44 (12.68%)  
Other 22 (5.64%) 55 (4.78%)  19 (5.48%) 20 (5.76%)  
Unspecified 37 (9.49%) 162 (14.07%)  33 (9.51%) 29 (8.36%)  
Comorbidity, N (%)       
Cirrhosis (all) 377 (96.67%) 968 (84.10%) <0.0001 337 (97.12%) 339 (97.69%) 0.6329 
Cirrhosis (alcoholic) 192 (49.23%) 518 (45.00%) 0.1479 176 (50.72%) 177 (51.01%) 0.9395 
















Hepatitis B 6 (1.54%) 26 (2.26%) 0.3885 4 (1.15%) 5 (1.44%) 0.7372 
Hepatitis C 100 (25.64%) 286 (24.85%) 0.7547 88 (25.36%) 86 (24.78%) 0.8610 
NAFLD 309 (79.23%) 809 (70.29%) 0.0006 273 (78.67%) 279 (80.40%) 0.5724 
Alcohol Abuse 218 (55.90%) 650 (56.47%) 0.8431 197 (56.77%) 201 (57.93%) 0.7588 
Diabetes 183 (46.92%) 477 (41.44%) 0.0587 162 (46.69%) 162 (46.69%) 1 
Renal Failure 119 (30.51%) 326 (28.32%) 0.4096 104 (29.97%) 107 (30.84%) 0.8045 
Elixhauser Comorbidity Index, 
mean (SD); median (IQR) 
53.9 (20.0)  
51 (40–68)  
52.4 (20.9)  
50 (37–67) 
0.1392 53.5 (19.4) 
51 (40–67)  
53.9 (19.9)  
52 (39–67) 
0.8657 
Labs       
Serum Creatinine, mean 





0.3103 1.3 (1.2) 
0.9 (0.7–1.3) 
1.3 (1.3)  
0.9 (0.7–1.3) 
0.6311 






















Ammonia, mean (SD); 
median (IQR)i 









Elevated WBC, N (%) 82 (21.03%) 219 (19.03%) 0.3895 71 (20.46%) 64 (18.44%) 0.5020 











MELD category, N (%)   0.1128   0.8777 
≤ 5 35 (8.97%) 153 (13.29%)  31 (8.93%) 25 (7.20%)  
6–10 93 (23.85%) 259 (22.50%)  82 (23.63%) 79 (22.77%)  
11–15 114 (29.49%) 337 (29.28%)  100 (28.82%) 102 (29.39%)  
16–20 64 (16.41%) 213 (18.51%)  60 (17.29%) 73 (21.04%)  
















26–30 27 (6.92%) 56 (4.87%)  23 (6.63%) 23 (6.63%)  
≥ 31 13 (3.33%) 24 (2.09%)  10 (2.59%) 8 (2.31%)  






<0.0001 14.1 (1.9)  
15 (14–15) 
14.2 (1.9)  
15 (14–15) 
0.0855 
GCS category, N (%)i   0.0086   0.8359 
Mild (13–15) 309 (86.07%) 965 (91.64%)  308 (88.76%) 311 (89.63%)  
Moderate (9–12) 33 (9.19%) 56 (5.32%)  29 (8.36%) 25 (7.20%)  
Severe (3–8) 17 (4.74%) 32 (3.04%)  10 (2.88%) 11 (3.17%)  
Prior Active Medications, N (%)       
Lactulose 120 (30.77%) 197 (17.12%) <0.0001 111 (31.99%) 78 (22.48%) 0.0049 
Rifaximin 108 (27.69%) 74 (6.43%) <0.0001 101 (29.11%) 28 (8.07%) <0.0001 
Index HE-related Hospitalization       












Position, N (%) 
      
1° – 8° Positions 238 (61.03%) 642 (55.78%) 0.0703 208 (59.94%) 190 (54.76%) 0.1671 
1° – 4° Positions 199 (51.03%) 482 (41.88%) 0.0017 172 (49.57%) 151 (43.52%) 0.1100 
1° – 2° Positions 178 (45.64%) 415 (36.06%) 0.0008 157 (45.24%) 134 (38.62%) 0.0768 
1° Position only 157 (40.26%) 373 (32.41%) 0.0048 140 (40.35%) 124 (35.73%) 0.2109 
Lactulose Active at 
Discharge, N (%) 
295 (75.64%) 542 (47.09%) <0.0001 260 (74.93%) 248 (71.47%) 0.3037 
i Results are reported using all available values. Missing values are excluded from the denominator unless otherwise reported. 
Table 3.1: Baseline Characteristics by Treatment Group and Cohort Type 
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In the unmatched cohort, patient demographics (age, gender, race, ethnicity, 
insurance type) were similar across treatment groups. Mean age in both rifaximin and 
control groups was 60 years, and most patients were less than 65 years old (67% vs. 64%, 
respectively), male (53% vs. 55%, respectively), white (82%, each), non-Hispanic (78% 
vs. 76%, respectively), and insured through Medicare (50% vs. 48%, respectively). Using 
an alpha of 0.2 to determine balance between cohorts, there were significantly higher 
proportions of patients in the rifaximin group with cirrhosis (all: 97% vs. 84%, P<0.0001; 
alcoholic: 49% vs. 45%, P=0.1479), non-alcoholic fatty liver disease (NAFLD: 79% vs. 
70%, P=0.0006), and diabetes (47% vs. 41%, P=0.0587) compared to the control group. 
However, there were lower proportions of patients in the rifaximin group with 
hepatocellular carcinoma (6% vs. 9%, P=0.1281). The distributions of Elixhauser 
comorbidity index (P=0.1392), MELD score (P=0.0924), and length of stay (LOS) of the 
index HE-related hospitalization (P=0.0005) were skewed higher in the rifaximin group vs. 
control group, and the distribution of Glasgow Coma Scale (GCS) score was skewed lower 
(P<0.0001) for rifaximin vs. control. Finally, a higher proportion of patients in the 
rifaximin group received lactulose at discharge (76% vs. 47%; P<0.0001) vs. control. 
Each of the statistically significant relationships noted in the analysis of the 
unmatched cohort above were corrected for through PS-matching procedures. Mean age 
(60 years) and the proportions of patients that were age <65 years (66%), male (52%), 
white (82%), and insured through Medicare (50%) were similar across treatment groups 
and to the means and proportions reported in the unmatched cohort. There were no 
statistically significant relationships between treatment groups and comorbidities, 





Hypothesis tests and results specific to objective 1 are summarized in Table 3.2: 
  
Objective 1: To evaluate the baseline characteristics of patients 












H0 1.2: The difference in proportions of patients by age category between 





H0 1.3: The difference in proportions of patients by gender between treatment 





H0 1.4: The difference in proportions of patients by race category between 





H0 1.5: The difference in proportions of patients by ethnicity between treatment 




H0 1.6: The difference in proportions of patients by primary insurance type 





H0 1.7: The differences in proportions of patients with select comorbidities at 
baseline between treatment groups are not statistically significant. 
Reject Fail to 
reject 
H0 1.8: The difference in patient comorbidity index between treatment groups is 
not statistically significant. 
Reject Fail to 
reject 
H0 1.9: The differences in individual laboratory measurements at baseline 
between treatment groups are not statistically significant. 
Reject Fail to 
reject 
H0 1.10: The difference in proportions of patients by MELD score category at 
baseline between treatment groups is not statistically significant 
Reject Fail to 
reject 
H0 1.11: The difference in proportions of patients by Glasgow Coma Scale 
category at baseline between treatment groups is not statistically significant. 
Reject Fail to 
reject 
H0 1.12: The difference in proportions of patients by prior medication use 
between treatment groups is not statistically significant. 
Reject Reject 
H0 1.13: The difference in length of stay at baseline between treatment groups is 
not statistically significant. 
Reject Fail to 
reject 
H0 1.14: The difference in proportion of patients with active lactulose orders at 
baseline between treatment groups is not statistically significant. 
Reject Fail to 
reject 
Table 3.2: Summary of Results by Hypothesis Test – Objective 1  
 
OUTCOME MEASURES 
Hospitalizations and emergency department (ED) visits are summarized by 
treatment group and cohort type in Table 3.3. Time-to-event analyses are also included for 
the pre-match cohort in Figure 3.2, and for the PS-matched cohort in Figure 3.3. 
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Patients with ≥1 Hospitalization       
At 180 days post-index       
All-cause 229 (58.72%) 614 (53.34%) 0.0654 202 (58.21%) 196 (56.48%) 0.6451 
Liver-related (any position) 225 (57.69%) 561 (48.74%) 0.0022 200 (57.64%) 192 (55.33%) 0.5402 
1° – 4° Positions only 178 (45.64%) 413 (35.88%) 0.0006 161 (46.40%) 138 (39.77%) 0.0779 
1° – 2° Positions only 144 (36.92%) 350 (30.41%) 0.0172 128 (36.89%) 123 (35.45%) 0.6928 
1° Position only 115 (29.49%) 298 (25.89%) 0.1658 101 (29.11%) 105 (30.26%) 0.7396 
HE-related (any position) 124 (31.79%) 311 (27.02%) 0.0702 111 (31.99%) 112 (32.28%) 0.9352 
1° – 4° Positions only 56 (14.36%) 138 (11.99%) 0.2228 52 (14.99%) 53 (15.27%) 0.9156 
1° – 2° Positions only 46 (11.79%) 121 (10.51%) 0.4814 42 (12.10%) 49 (14.12%) 0.4312 
1° Position only 39 (10.00%) 113 (9.82%) 0.9168 36 (10.37%) 47 (13.54%) 0.1982 
At 30 days post-index       
All-cause 122 (31.28%) 308 (26.76%) 0.0853 107 (30.84%) 101 (29.11%) 0.6191 
Liver-related (any position) 118 (30.26%) 280 (24.33%) 0.0208 105 (30.26%) 99 (28.53%) 0.6171 
1° – 4° Positions only 81 (20.77%) 190 (16.51%) 0.0560 73 (21.04%) 70 (20.17%) 0.7783 
1° – 2° Positions only 66 (16.92%) 153 (13.29%) 0.0760 60 (17.29%) 57 (16.43%) 0.7610 
1° Position only 49 (12.56%) 129 (11.21%) 0.4689 46 (13.26%) 49 (14.12%) 0.7404 
HE-related (any position) 55 (14.10%) 143 (12.42%) 0.3919 48 (13.83%) 49 (14.12%) 0.9128 
1° – 4° Positions only 21 (5.38%) 57 (4.95%) 0.7364 19 (5.48%) 24 (6.92%) 0.4311 
1° – 2° Positions only 17 (4.36%) 51 (4.43%) 0.9523 15 (4.32%) 21 (6.05%) 0.3044 
1° Position only 15 (3.85%) 45 (3.91%) 0.9553 14 (4.03%) 19 (5.48%) 0.3725 
Patients with ≥1 ED Visit       
At 180 days post-index       
All-cause 244 (62.56%) 651 (56.56%) 0.0378 220 (63.40%) 216 (62.25%) 0.7534 
Liver-related (any position) 227 (58.21%) 559 (48.57%) 0.0010 206 (59.37%) 198 (57.06%) 0.5381 
1° – 4° Positions only 184 (47.18%) 430 (37.36%) 0.0006 169 (48.70%) 150 (43.23%) 0.1478 
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1° – 2° Positions only 137 (35.13%) 365 (31.71%) 0.2134 124 (35.73%) 129 (37.18%) 0.6933 
1° Position only 103 (26.41%) 291 (25.28%) 0.6590 93 (26.80%) 104 (29.97%) 0.3544 
HE-related (any position) 99 (25.38%) 266 (23.11%) 0.3612 89 (25.65%) 97 (27.95%) 0.4930 
1° – 4° Positions only 48 (12.31%) 125 (10.86%) 0.4339 45 (12.97%) 47 (13.54%) 0.8228 
1° – 2° Positions only 40 (10.26%) 108 (9.38%) 0.6130 37 (10.66%) 43 (12.39%) 0.4757 
1° Position only 34 (8.72%) 100 (8.69%) 0.9856 32 (9.22%) 41 (11.82%) 0.2655 
At 30 days post-index       
All-cause 139 (35.64%) 354 (30.76%) 0.0739 123 (35.45%) 120 (34.58%) 0.8113 
Liver-related (any position) 128 (32.82%) 293 (25.46%) 0.0048 113 (32.56%) 106 (30.55%) 0.5675 
1° – 4° Positions only 89 (22.82%) 207 (17.98%) 0.0361 80 (23.05%) 78 (22.48%) 0.8563 
1° – 2° Positions only 61 (15.64%) 171 (14.86%) 0.7081 55 (15.85%) 66 (19.02%) 0.2711 
1° Position only 42 (10.77%) 134 (11.64%) 0.6395 39 (11.24%) 51 (14.70%) 0.1751 
HE-related (any position) 47 (12.05%) 119 (10.34%) 0.3458 40 (11.53%) 42 (12.10%) 0.8141 
1° – 4° Positions only 20 (5.13%) 54 (4.69%) 0.7274 18 (5.19%) 23 (6.63%) 0.4208 
1° – 2° Positions only 15 (3.85%) 48 (4.17%) 0.7800 13 (3.75%) 20 (5.76%) 0.2118 
1° Position only 14 (3.59%) 42 (3.65%) 0.9569 13 (3.75%) 18 (5.19%) 0.3582 
Mortality (all-cause) 72 (18.46%) 229 (19.90%) 0.5370 65 (18.73%) 68 (19.60%) 0.7723 











HR: 1.154; 95% CI [0.991, 1.343]; 
P=0.0650 
HR: 1.273; 95% CI [1.091, 1.487]; 
P=0.0022 








HR: 1.176; 95% CI [1.015, 1.362]; 
P=0.0313 
HR: 1.304; 95% CI [1.117, 1.521]; 
P=0.0008 
HR: 1.110; 95% CI [0.881, 1.398]; 
P=0.3753 
Figure 3.2: Kaplan-Meier Curves and Cox Proportional Hazards Ratios for Healthcare Utilization Measures (pre-match) 
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HR: 1.045; 95% CI [0.858, 1.271]; 
P=0.6638 
HR: 1.061; 95% CI [0.870, 1.293]; 
P=0.5605 








HR: 1.034; 95% CI [0.857, 1.248]; 
P=0.7239 
HR: 1.061; 95% CI [0.873, 1.289]; 
P=0.5539 
HR: 0.900; 95% CI [0.675, 1.199]; 
P=0.4710 
Figure 3.3: Kaplan-Meier Curves and Cox Proportional Hazards Ratios for Healthcare Utilization Measures (post-match) 
  
             
             
            
                   
   
   
   
   
   
   
 
 











                                  
                           
                               
 
 







   
  
                
             
             
            
                       
   
   
   
   
   
   
 
 











                                  
                           
                               
 
 







   
  
                
             
             
            
                      
   
   
   
   
   
   
 
 











                                  
                           
                               
 
 







   
  
                
             
             
            
                  
   
   
   
   
   
   
 
 











                                  
                           
                               
 
 







   
  
                
             
             
            
                      
   
   
   
   
   
   
 
 











                                  
                           
                               
 
 







   
  
                
             
             
            
                     
   
   
   
   
   
   
 
 











                                  
                           
                               
 
 







   
  




In the unmatched cohort (N=390, rifaximin; N=1,151, control), at least one all-
cause hospitalization occurred within 180 days in 229 (58.72%) patients in the rifaximin 
group, compared to 614 (53.34%, P=0.0654) patients in the control group. Similarly, there 
was no statistically significant relationship between treatment group and all-cause 
hospitalization at 30 days (31.28% vs. 26.76%, P=0.0853). There were higher proportions 
of patients with liver-related hospitalizations using any diagnosis position in the rifaximin 
group (180 days: 57.69%; 30 days: 30.26%) compared to control (180 days: 48.74%, 
P=0.0006; 30 days: 24.33%, P=0.0208); however, these results were sensitive to diagnosis 
position, as there were no statistically significant relationships in either measure when 
using diagnoses in the primary position only. HE-related hospitalizations within 180 & 30 
days occurred in 124 (31.79%) & 55 (14.10%) patients in the rifaximin group, respectively, 
and in 311 (27.02%, P=0.0702) & 143 (12.42%, P=0.3919) patients in the control group, 
respectively. In the time-to-event analyses, rifaximin was associated with 27% higher risk 
of liver-related hospitalization (HR: 1.273; 95% CI [1.091, 1.487]; P=0.0022) vs. control, 
but there were no statistically significant differences between treatment groups in risk of 
all-cause (HR: 1.154; 95% CI [0.991, 1.343]; P=0.0650) or HE-related (HR: 1.200; 95% 
CI [0.975, 1.478]; P=0.0858) hospitalizations. 
In the PS-matched cohort (N=347, both groups), there were no statistically 
significant relationships between treatment groups (rifaximin vs. control) and proportions 
of patients with all-cause (180 days: 58.21% vs. 56.48%, P=0.6451; 30 days: 30.84% vs. 
29.11%, P=0.6191), liver-related (180 days: 57.64% vs. 55.33%, P=0.5402; 30 days: 
30.26% vs. 28.53%, P=0.6171), or HE-related (180 days: 31.99% vs. 32.28%, P=0.9352; 
30 days: 13.83% vs. 14.12%, P=0.9128) hospitalizations. Similarly, time-to-event analyses 
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revealed no differences in risk for all-cause (HR: 1.045; 95% CI [0.858, 1.271]; P=0.6638), 
liver-related (HR: 1.061; 95% CI [0.870, 1.293]; P=0.5605), or HE-related (HR: 0.983; 
95% CI [0.756, 1.278]; P=0.8966) hospitalizations in the rifaximin group vs. control. 
ED Visits 
In the unmatched cohort, there were significantly higher proportions of patients in 
the rifaximin group vs. control with at least one all-cause ED visit at 180 days (62.56% vs. 
56.56%, P=0.0378), liver-related ED visit at 180 days (58.21% vs. 48.57%, P=0.0010) & 
30 days (32.82% vs. 25.46%, P=0.0048). However, proportions of patients with at least 
one ED visit where the liver-related diagnosis was in the primary position did not 
significantly differ between rifaximin and control groups (180 days: 26.41% vs. 25.28%, 
P=0.6590; 30 days: 10.77% vs. 11.64%, P=0.6395). There were also no significant 
relationships between treatment group and all-cause ED visits at 30 days (35.64% vs. 
30.76%, P=0.0739), HE-related ED visits at 180 days (25.38% vs. 25.28%, P=0.6590), and 
HE-related ED visits at 30 days (12.05% vs. 10.34%; P=0.3458). Rifaximin was associated 
with 18% higher risk of all-cause ED visits (HR: 1.176; 95% CI [1.015, 1.362]; P=0.0313), 
and 30% higher risk liver-related ED visits (HR: 1.304; 95% CI [1.117, 1.521]; P=0.0008) 
vs. control, but there was no statistically significant difference between treatment groups 
in risk of HE-related (HR: 1.110; 95% CI [0.881, 1.398]; P=0.3753) ED visits. 
In the PS-matched cohort, there were no statistically significant relationships 
between treatment groups (rifaximin vs. control) and all-cause (180 days: 63.40% vs. 
62.25%, P=0.7534; 30 days: 35.45% vs. 34.58%, P=0.8113), liver-related (180 days: 
59.37% vs. 57.06%, P=0.5381; 30 days: 32.56% vs. 30.55%, P=0.5675), or HE-related 
(180 days: 25.65% vs. 27.95%, P=0.4930; 30 days: 11.53% vs. 12.10%, P=0.8141). There 
were also no differences between treatment groups in risk for all-cause (HR: 1.034; 95% 
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CI [0.857, 1.248]; P=0.7239), liver-related (HR: 1.061; 95% CI [0.873, 1.289]; P=0.5539), 
or HE-related (HR: 0.900; 95% CI [0.675, 1.199]; P=0.4710) ED visits. 
Hypothesis tests and results specific to Objective 2 are summarized in Table 3.4: 
 
Objective 2: To compare healthcare utilization metrics in patients 
that did or did not receive rifaximin following the first qualifying 






H0 2.1: The difference in proportions of patients with at least one all-cause 





H0 2.2: The difference in proportions of patients with at least one liver-related 
hospitalization at 180 days between treatment groups is not statistically significant. 
Reject Fail to 
reject 
H0 2.3: The difference in proportions of patients with at least one HE-related 





H0 2.4: The difference in proportions of patients with at least one all-cause 





H0 2.5: The difference in proportions of patients with at least one liver-related 
hospitalization at 30 days between treatment groups is not statistically significant. 
Reject Fail to 
reject 
H0 2.6: The difference in proportions of patients with at least one HE-related 





H0 2.7: The difference in proportions of patients with at least one all-cause ED visit 





H0 2.8: The difference in proportions of patients with at least one liver-related ED 
visit at 180 days between treatment groups is not statistically significant. 
Reject Fail to 
reject 
H0 2.9: The difference in proportions of patients with at least one HE-related ED 





H0 2.10: The difference in proportions of patients with at least one all-cause ED 





H0 2.11: The difference in proportions of patients with at least one liver-related ED 
visit at 30 days between treatment groups is not statistically significant. 
Reject Fail to 
reject 
H0 2.12: The difference in proportions of patients with at least one HE-related ED 





H0 2.13: The difference in time to first all-cause hospitalization between treatment 





H0 2.14: The difference in time to first liver-related hospitalization between 
treatment groups is not statistically significant. 
Reject Fail to 
reject 
H0 2.15: The difference in time to first HE-related hospitalization between 





H0 2.16: The difference in time to first all-cause ED visit between treatment groups 
is not statistically significant. 
Reject Fail to 
reject 
H0 2.17: The difference in time to first liver-related ED visit between treatment 
groups is not statistically significant. 
Reject Fail to 
reject 
H0 2.18: The difference in time to first HE-related ED-visit between treatment 









Of 1,541 patients included in the study, 301 (19.5%) died within 180 days post-
index. There were no statistically significant differences between rifaximin vs. control in 
the proportion of patients that died pre-match (18.5% vs. 19.9%; P=0.5370) or post-match 
(18.7% vs. 19.6%; P=0.7723). Time-to-event analysis also showed no significant 
differences between treatment groups in risk of death pre-match (HR: 0.914; 95% CI 
[0.701, 1.191]; P=0.5053) or post-match (HR: 0.953; 95% CI [0.678, 1.339]; P=0.7804). 
Adherence 
Of 1,541 patients included in the study, 36 (2.3%) patients were continuously 
enrolled in the Scott & White Health Plan (SWHP) for 6 months pre- and 6 months post-
index date. Proportions of patients with medication claims post-index, and proportion of 
days covered (PDC) ratio ≥ 0.8 are reported by the corresponding absence or presence of 
orders for each respective medication in Table 3.4 below: 
 






 N (%) 
Cohen’s 
Kappa (κ) 
Rifaximin (any claim)    0.1702 
No Claim 18 (50.00%) 7 (19.44%) 25 (69.44%)  
Claim 6 (16.67%) 5 (13.89%) 11 (30.56%)  
Total 24 (66.67%) 12 (33.33%) 36 (100%)  
Rifaximin (PDC)    0.1000 
<80% 22 (61.11%) 10 (27.78%) 32 (88.89%)  
≥80% 2 (5.56%) 2 (5.56%) 4 (11.11%)  
Total 24 (66.67%) 12 (33.33%) 36 (100%)  
Lactulose (any claim)    0.1818 
No Claim 8 (22.22%) 11 (30.56%) 19 (52.78%)  
Claim 4 (11.11%) 13 (36.11%) 17 (47.22%)  
Total 12 (33.33%) 24 (66.67%) 36 (100%)  
Lactulose (PDC)    -0.0286 
<80% 11 (30.56%) 23 (63.89%) 34 (94.44%)  
≥80% 1 (2.78%) 1 (2.78%) 2 (5.56%)  
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Total 12 (33.33%) 24 (66.67%) 36 (100%)  
Green = agreement, Red = disagreement 
Table 3.5: Medication Order vs. Medication Claims Data in SWHP Study Patients 
There were 12 (33.33%) patients with active rifaximin orders, 11 (30.56%) patients 
with at least one medication claim for rifaximin (63.89% agreement, κ=0.1702), and 4 
(11.11%) patients with PDC ≥ 0.8 (66.67% agreement, κ=0.1000). Of the 11 patients that 
had a claim for rifaximin, 4 (36.37%) patients were adherent with PDC ≥ 0.8. For lactulose, 
there were 24 (66.67%) patients with active medication orders, 17 (47.22%) patients with 
at least one medication claim (58.33% agreement, κ=0.1818), and 2 (5.56%) patients with 
PDC ≥ 0.8 (33.33% agreement, κ=-0.0286). Of the 17 patients that had a claim for 
lactulose, 2 (11.76%) patients were adherent with PDC ≥ 0.8. 
Hypothesis tests and results specific to Objective 3 are summarized in Table 3.6: 
 
Objective 3: To assess the accuracy of using EHR data to define 
medication use in patients prescribed rifaximin as prophylaxis for HE. 
Results 
H0 3.1: The difference in proportions of patients with rifaximin ordered vs. filled data is 
not statistically significant. 
Reject 
H0 3.2: The difference in proportions of patients with rifaximin ordered vs. proportion of 
days covered by rifaximin ≥80% is not statistically significant. 
Reject 






Two sensitivity analyses were conducted to describe how HE-related diagnosis 
position used for inclusion criteria, and crossover between treatment groups impact 
healthcare utilization measures. Result tables for these analyses are in Appendix B. 
Diagnosis Position 
Five scenarios were evaluated with increasing levels of restriction on position 
required for the HE-related diagnosis used for study inclusion. This yielded the following 
number of study patients pre-match and post-match:  
(1) any position (N=1,541, pre-; N=694, post-),  
(2) positions 1–8 only (N=880, pre-; N=390, post-),  
(3) positions 1–4 only (N=681, pre-; N=320, post-),  
(4) primary or secondary positions only (N=593, pre-; N=288, post-), and 
(5) primary position only (N=530, pre-; N=256, post-). 
 Increasing levels of restriction on diagnosis position did not produce substantially 
different results in the proportions of patients with at least one event. The largest ranges in 
proportions pre-match were found in HE-related hospitalizations at 180 days (28.23–
32.64%), liver-related ED visits at 180 days (51.01–56.04%), and HE-related ED-visits at 
180 days (23.69–28.68%), each trending higher with increasing levels of restriction. Across 
each of the PS-matched cohorts, the largest ranges in proportions included all-cause 
hospitalizations at 30 days (24.22–29.97%), liver-related hospitalizations at 30 days 
(24.22–29.39%), and liver-related ED visits at 30 days (27.34–31.56%), each trending 




Crossover from control to rifaximin, defined as a new order for rifaximin after the 
index date but prior to any hospitalization or ED-visit, was detected in 63 (5.5%) patients 
in the control group. In patients where crossover was detected, time to crossover was 1–7 
days for 12 (19%) patients, 8–30 days for 24 (38%) patients, 31–90 days for 19 (30%) 
patients, and 91–180 days for 8 (19%) patients. With re-assignment of these patients to the 
rifaximin group, pre-match, liver-related, 30-day hospitalizations (rifaximin: 27.59%, 
control 25.09%, P=0.3066) and ED visits (rifaximin: 29.80%, control: 26.29%, P=0.1584) 
were no longer significantly associated with treatment group. Otherwise, there were no 




Chapter 4:  Discussion 
DISCUSSION 
This retrospective cohort study evaluated the impact of active rifaximin medication 
orders on healthcare utilization measures in real-world patients following discharge from 
hospitalization due to hepatic encephalopathy (HE). Although several baseline 
characteristics were unbalanced across treatment groups in the full study cohort, propensity 
score (PS) matching techniques controlled for these differences while also including 
enough patients to meet 80% power. Results from the PS-matched analysis showed no 
statistically significant differences in all-cause, liver-related, or HE-related hospitalizations 
or ED visits at either 30 or 180 days. These results were not sensitive to different criteria 
for diagnosis position (used either for study inclusion or outcome measurement) or re-
assignment based on detectable crossover. However, there was little to no agreement 
between medication orders and medication claims or adherence, emphasizing the 
importance of distinguishing between medication orders and medication use when 
interpreting results from the analysis of healthcare utilization measures.  
Compared to the pivotal, randomized controlled trial that demonstrated efficacy of 
rifaximin in reducing HE-related hospitalizations,28 patients included in the PS-matched 
cohort of this study on average were older (60 vs. 56 years) and had more advanced liver 
disease (MELD ≥26: 11% vs. 0%). Patients with gastrointestinal bleeding, renal or 
respiratory insufficiency, anemia, electrolyte abnormality, infection, or spontaneous 
bacterial peritonitis, were excluded from the clinical trial, but were not excluded from this 
study. The overall presence of HE-related hospitalizations at 168 days in the clinical trial 
was approximately 18%, which was within the range of HE-related hospitalization rates at 
180 days observed in this study (12%, primary position only; 32%, any position). However, 
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differences in HE-related hospitalizations between treatment groups observed in clinical 
trials was not seen in this study, which could potentially be explained by lack of access or 
poor adherence to rifaximin as seen in the subgroup of patients where medication claims 
data could be assessed. A high comorbidity burden, as was observed in this study sample, 
is also likely to result in high all-cause hospitalization rate, which was not evaluated in the 
clinical trial. 
While adherence to rifaximin was efficacious in specific patient populations in 
clinical trial settings, these same results may not always be seen in broader, real-world 
populations. Cost-effectiveness analyses that rely on these results as assumptions are likely 
to overestimate the potential cost-savings opportunity from decreased hospitalizations. As 
such, it is important to consider the complex nature of this disease state and incorporate a 
wide range of possible outcomes when conducting cost-effectiveness analyses. 
Pharmacists are uniquely positioned to help improve patient outcomes in patients 
with HE. While medications may be ordered at discharge, timely completion of prior 
authorizations are needed to ensure patient access to therapy. Effective medication 
counseling at discharge can improve patient education and adherence, increasing the 
number of patients that receive maximal benefit from medications. Future research should 
focus on patient-specific factors and patient education strategies that lead to higher 






Due to the retrospective design of the study, there are several potential sources of 
bias, including poor control over the exposure factor, covariates, and potential confounders. 
Because this study primarily relies on EHR data, hospitalizations and ED visits occurring 
outside of the BSWH system are not captured. Medication orders documented in the EHR 
do not necessarily correlate with medication fills or adherence. Errors made in the selection 
and positioning of diagnosis codes in the EHR may lead to imprecisions in patient selection 
and/or outcome measures, though sensitivity analyses showed little impact of different 
positions of diagnosis codes on differences in outcome measures between treatment 
groups. Lastly, results of this study may not be generalizable to broader populations outside 
of the BSWH system. 
 
CONCLUSIONS 
After controlling for measurable covariates, patients discharged from an HE-related 
hospitalization on average experienced no statistically significant differences in all-cause, 
liver-related, or HE-related hospitalizations, ED visits at 30 or 180 days, or mortality rates 
with or without a rifaximin order at discharge. While rifaximin was shown to be efficacious 
in clinical trials, patients with greater disease burden as well as barriers to adherence may 
limit the cost-effectiveness of rifaximin in real-world settings. Future research should 
incorporate real-world data in cost-effectiveness analyses and assess the impact of patient-




Appendix A: Diagnosis Code Lists 
 




ICD-10-CM: K72.10, K72.11, K72.90, K72.91 
Liver-related 
Diagnoses 
ICD-9-CM: 070.22, 070.23, 070.32, 070.33, 070.44, 070.54, 070.6, 070.9, 456.0–
456.2, 570.x, 571.x, 572.2–572.8, 573.3, 573.4, 573.8, 573.9, V42.7 
ICD-10-CM: B18.x, I85.x, I86.4, I98.2, K70.x, K71.1, K71.3–K71.5, K71.7, 
K72.x–K74.x, K76.0, K76.2–K76.9, Z94.4 
Cirrhosis, any 
ICD-9-CM: 571.2, 571.5 










ICD-9-CM: 070.2x, 070.3x 
ICD-10-CM: B16.x, B18.0, B18.1, B19.1x 
Hepatitis C 
ICD-9-CM: 070.41, 070.44, 070.51, 070.54, 070.7x 
ICD-10-CM: B17.1x, B18.2, B19.2x 
NAFLD/NASH 
ICD-9-CM: 571.5, 571.8, 571.9 
ICD-10-CM: K75.81, K76.0 
Alcohol Abuse 
ICD-9-CM: 265.2, 291.1–291.3, 291.5–291.9, 303.0, 303.9, 305.0, 357.5, 425.5, 
535.3, 571.0–571.3, 980.x, V11.3 






ICD-9-CM: 403.01, 403.11, 403.91, 404.02, 404.03, 404.12, 404.13, 404.92, 
404.93, 585.x, 586.x, 588.0, V42.0, V45.1, V56.x 
ICD-10-CM: I12.0, I13.1, N18.x, N19.x, N25.0, Z49.0–Z49.2, Z94.0, Z99.2 





Comorbidity Code List 
AIDS/HIV 
ICD-9-CM: 042.x–044.x 
ICD-10-CM: B20.x–B22.x, B24.x 
Alcohol Abuse 
ICD-9-CM: 265.2, 291.1–291.3, 291.5–291.9, 303.0, 303.9, 305.0, 357.5, 
425.5, 535.3, 571.0–571.3, 980.x, V11.3 
ICD-10-CM: F10, E52, G62.1, I42.6, K29.2, K70.0, K70.3, K70.9, T51.x, 
Z50.2, Z71.4, Z72.1 
Deficiency 
Anemia 
ICD-9-CM: 280.1–280.9, 281.x 





ICD-9-CM: 446.x, 701.0, 710.0–710.4, 710.8, 710.9, 711.2, 714.x, 719.3, 
720.x, 725.x, 728.5, 728.89, 729.30 
ICD-10-CM: L94.0, L94.1, L94.3, M05.x, M06.x, M08.x, M12.0, M12.3, 







ICD-9-CM: 398.91, 402.01, 402.11, 402.91, 404.01, 404.03, 404.11, 404.13, 
404.91, 404.93, 425.4–425.9, 428.x 





ICD-9-CM: 416.8, 416.9, 490.x–505.x, 506.4, 508.1, 508.8 
ICD-10-CM: I27.8, I27.9, J40.x–J47.x, J60.x–J67.x, J68.4, J70.1, J70.3 
Coagulopathy 
ICD-9-CM: 286.x, 287.1, 287.3–287.5 
ICD-10-CM: D65–D68.x, D69.1, D69.3–D69.6 
Depression 
ICD-9-CM: 296.2, 296.3, 296.5, 300.4, 309.x, 311 
ICD-10-CM: F20.4, F31.3 - F31.5, F32.x, F33.x, F34.1, F41.2, F43.2 
Diabetes, 
uncomplicated 
ICD-9-CM: 250.0 - 250.3 
ICD-10-CM: E10.0, E10.1, E10.9, E11.0, E11.1, E11.9, E12.0, E12.1, E12.9, 




ICD-10-CM: E10.2–E10.8, E11.2–E11.8, E12.2–E12.8, E13.2–E13.8, E14.2–
E14.8 
Drug Abuse 
ICD-9-CM: 292.x, 304.x, 305.2–305.9, V65.42 




ICD-10-CM: I11.x–I13.x, I15.x 
Hypothyroidism 
ICD-9-CM: 240.9, 243.x, 244.x, 246.1, 246.8 
ICD-10-CM: E00.x–E03.x, E89.0 
Liver Disease 
ICD-9-CM: 070.22, 070.23, 070.32, 070.33, 070.44, 070.54, 070.6, 070.9, 
456.0–456.2, 570.x, 571.x, 572.2–572.8, 573.3, 573.4, 573.8, 573.9, V42.7 
ICD-10-CM: B18.x, I85.x, I86.4, I98.2, K70.x, K71.1, K71.3–K71.5, K71.7, 




ICD-9-CM: 200.x–202.x, 203.0, 238.6 




ICD-9-CM: 253.6, 276.x 







ICD-9-CM: 331.9, 332.0, 332.1, 333.4, 333.5, 333.92, 334.x - 335.x, 336.2, 
340.x, 341.x, 345.x, 348.1, 348.3, 780.3, 784.3 
ICD-10-CM: G10.x–G13.x, G20.x–G22.x, G25.4, G25.5, G31.2, G31.8, G31.9, 





ICD-9-CM: 334.1, 342.x, 343.x, 344.0 - 344.6, 344.9 




ICD-9-CM: 093.0, 437.3, 440.x, 441.x, 443.1–443.9, 447.1, 557.1, 557.9, 
V43.4 
ICD-10-CM: I70.x, I71.x, I73.1, I73.8, I73.9, I77.1, I79.0, I79.2, K55.1, K55.8, 
K55.9, Z95.8, Z95.9 
Psychoses 
ICD-9-CM: 293.8, 295.x, 296.04, 296.14, 296.44, 296.54, 297.x, 298.x 




ICD-9-CM: 415.0, 415.1, 416.x, 417.0, 417.8, 417.9 
ICD-10-CM: I26.x, I27.x, I28.0, I28.8, I28.9 
Renal Failure 
ICD-9-CM: 403.01, 403.11, 403.91, 404.02, 404.03, 404.12, 404.13, 404.92, 
404.93, 585.x, 586.x, 588.0, V42.0, V45.1, V56.x 




ICD-9-CM: 140.x–172.x, 174.x–195.x 




ICD-9-CM: 531.7, 531.9, 532.7, 532.9, 533.7, 533.9, 534.7, 534.9 
ICD-10-CM: K25.7, K25.9, K26.7, K26.9, K27.7, K27.9, K28.7, K28.9 
Valvular Disease 
ICD-9-CM: 093.2, 394.x–397.x, 424.x, 746.3–746.6, V42.2, V43.3 
ICD-10-CM: A52.0, I05.x–I08.x, I09.1, I09.8, I34.x–I39.x, Q23.0–Q23.3, 
Z95.2–Z95.4 
Weight Loss 
ICD-9-CM: 260.x–263.x, 783.2, 799.4 
ICD-10-CM: E40.x–E46.x, R63.4, R64 
Table A.2: Diagnosis Code List for Elixhauser Comorbidity Index [Adapted]46
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Appendix B: Sensitivity Analysis Results 
 
Measure, N (%) 
Pre-Match, Baseline HE Diagnosis Position 
Any Position 
(N=1,541) 
1° – 8° 
Positions 
(N=880)  
1° – 4° 
Positions 
(N=681) 






Patients with ≥1 Hospitalization      
At 180 days post-index      
All-cause 843 (54.70%) 465 (52.84%) 368 (54.04%) 332 (55.99%) 298 (56.23%) 
Liver-related (any position) 786 (51.01%) 442 (50.23%) 355 (52.13%) 322 (54.30%) 289 (54.53%) 
HE-related (any position) 435 (28.23%) 256 (29.09%) 211 (30.98%) 188 (31.70%) 173 (32.64%) 
At 30 days post-index      
All-cause 430 (27.90%) 221 (25.11%) 171 (25.11%) 153 (25.80%) 136 (25.66%) 
Liver-related (any position) 398 (25.83%) 211 (23.98%) 166 (24.38%) 149 (25.13%) 135 (25.47%) 
HE-related (any position) 198 (12.85%) 106 (12.05%) 85 (12.48%) 74 (12.48%) 68 (12.83%) 
Patients with ≥1 ED Visit      
At 180 days post-index      
All-cause 895 (58.08%) 505 (57.39%) 405 (59.47%) 363 (61.21%) 328 (61.89%) 
Liver-related (any position) 786 (51.01%) 451 (51.25%) 361 (53.01%) 328 (55.31%) 297 (56.04%) 
HE-related (any position) 365 (23.69%) 220 (25.00%) 184 (27.02%) 166 (27.99%) 152 (28.68%) 
At 30 days post-index      
All-cause 493 (31.99%) 261 (29.66%) 202 (29.66%) 181 (30.52%) 162 (30.57%) 
Liver-related (any position) 421 (27.32%) 229 (26.02%) 177 (25.99%) 159 (26.81%) 142 (26.79%) 
HE-related (any position) 166 (10.77%) 92 (10.45%) 76 (11.16%) 67 (11.30%) 61 (11.51%) 
Table B.1. Healthcare Utilization Measures by Baseline HE-related Diagnosis Position (Pre-Match)  
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Measure, N (%) 
Post-Match*, Baseline HE Diagnosis Position 
Any Position 
(N=694) 
1° – 8° 
Positions 
(N=390)  
1° – 4° 
Positions 
(N=320) 






Patients with ≥1 Hospitalization      
At 180 days post-index      
All-cause 398 (57.35%) 217 (55.64%) 173 (54.06%) 160 (55.56%) 146 (57.03%) 
Liver-related (any position) 392 (56.48%) 213 (54.62%) 171 (53.44%) 158 (54.86%) 145 (56.64%) 
HE-related (any position) 223 (32.13%) 123 (31.54%) 104 (32.50%) 91 (31.60%) 82 (32.03%) 
At 30 days post-index      
All-cause 208 (29.97%) 107 (27.44%) 81 (25.31%) 70 (24.31%) 62 (24.22%) 
Liver-related (any position) 204 (29.39%) 105 (26.92%) 81 (25.31%) 69 (23.96%) 62 (24.22%) 
HE-related (any position) 97 (13.98%) 50 (12.82%) 43 (13.44%) 31 (10.76%) 31 (12.11%) 
Patients with ≥1 ED Visit      
At 180 days post-index      
All-cause 436 (62.82%) 241 (61.79%) 201 (62.81%) 184 (63.89%) 170 (66.41%) 
Liver-related (any position) 404 (58.21%) 223 (57.18%) 183 (57.19%) 170 (59.03%) 156 (60.94%) 
HE-related (any position) 186 (26.80%) 102 (26.15%) 95 (29.69%) 82 (28.47%) 75 (29.30%) 
At 30 days post-index      
All-cause 243 (35.01%) 129 (33.08%) 104 (32.50%) 189 (30.90%) 83 (32.42%) 
Liver-related (any position) 219 (31.56%) 114 (29.23%) 90 (28.13%) 77 (26.74%) 70 (27.34%) 
HE-related (any position) 82 (11.82%) 40 (10.26%) 41 (12.81%) 30 (10.42%) 29 (11.33%) 
*Note: Separate PS-Matching procedures were performed on each cohort by rule for diagnosis position (from Table 3) 




Measure, N (%) 
Time (Days) from Index Date to Rifaximin Order 
Total 
(N=63) 
At 1–7 days 
(N=12) 






Patients with ≥1 Hospitalization      
At 180 days post-index      
All-cause 6 (50.00%) 13 (54.17%) 8 (42.11%) 0 (0.00%) 27 (42.86%) 
Liver-related (any position) 6 (50.00%) 13 (54.17%) 7 (36.84%) 0 (0.00%) 26 (41.27%) 
HE-related (any position) 6 (50.00%) 5 (20.83%) 4 (21.05%) 0 (0.00%) 15 (23.81%) 
At 30 days post-index      
All-cause 2 (16.67%) 5 (20.83%) 0 (0.00%) 0 (0.00%) 7 (11.11%) 
Liver-related (any position) 2 (16.67%) 5 (20.83%) 0 (0.00%) 0 (0.00%) 7 (11.11%) 
HE-related (any position) 1 (8.33%) 1 (4.17%) 0 (0.00%) 0 (0.00%) 2 (3.17%) 
Patients with ≥1 ED Visit      
At 180 days post-index      
All-cause 5 (41.67%) 12 (50.00%) 7 (36.84%) 0 (0.00%) 24 (38.10%) 
Liver-related (any position) 5 (41.67%) 12 (50.00%) 7 (36.84%) 0 (0.00%) 24 (38.10%) 
HE-related (any position) 4 (33.33%) 4 (16.67%) 4 (21.05%) 0 (0.00%) 12 (19.05%) 
At 30 days post-index      
All-cause 2 (16.67%) 5 (20.83%) 0 (0.00%) 0 (0.00%) 7 (11.11%) 
Liver-related (any position) 2 (16.67%) 5 (20.83%) 0 (0.00%) 0 (0.00%) 7 (11.11%) 
HE-related (any position) 0 (0.00%) 0 (0.00%) 0 (0.00%) 0 (0.00%) 0 (0.00%) 
















Patients with ≥1 Hospitalization       
At 180 days post-index       
All-cause 256 (56.51%) 587 (53.95%) 0.3577 225 (56.11%) 225 (56.11%) 1 
Liver-related (any position) 251 (55.41%) 535 (49.17%) 0.0257 221 (55.11%) 217 (54.11%) 0.7766 
1° – 4° Positions only 196 (43.27%) 395 (36.31%) 0.0104 177 (44.14%) 157 (39.15%) 0.1520 
1° – 2° Positions only 160 (35.32%) 334 (30.70%) 0.0766 143 (35.66%) 129 (32.17%) 0.2964 
1° Position only 130 (28.70%) 283 (26.01%) 0.2780 115 (28.68%) 112 (27.93%) 0.8141 
HE-related (any position) 139 (30.68%) 296 (27.21%) 0.1670 123 (30.67%) 125 (31.17%) 0.8786 
1° – 4° Positions only 62 (13.69%) 132 (12.13%) 0.4021 57 (14.21%) 61 (15.21%) 0.6901 
1° – 2° Positions only 52 (11.48%) 115 (10.57%) 0.6009 47 (11.72%) 56 (13.97%) 0.3422 
1° Position only 45 (9.93%) 107 (9.83%) 0.9525 41 (10.22%) 51 (12.72%) 0.2678 
At 30 days post-index       
All-cause 129 (28.48%) 301 (27.67%) 0.7463 114 (28.43%) 109 (27.18%) 0.6935 
Liver-related (any position) 125 (27.59%) 273 (25.09%) 0.3066 111 (27.68%) 105 (26.18%) 0.6329 
1° – 4° Positions only 84 (18.54%) 187 (17.19%) 0.5243 76 (18.95%) 71 (17.71%) 0.6482 
1° – 2° Positions only 68 (15.01%) 151 (13.88%) 0.5619 62 (15.46%) 55 (13.72%) 0.4838 
1° Position only 50 (11.04%) 128 (11.76%) 0.6841 47 (11.72%) 46 (11.47%) 0.9122 
HE-related (any position) 57 (12.58%) 141 (12.96%) 0.8404 49 (12.22%) 55 (13.72%) 0.5283 
1° – 4° Positions only 21 (4.64%) 57 (5.24%) 0.6226 19 (4.74%) 25 (6.23%) 0.3522 
1° – 2° Positions only 17 (3.75%) 51 (4.69%) 0.4157 15 (3.74%) 24 (5.99%) 0.1395 
1° Position only 15 (3.31%) 45 (4.14%) 0.4458 14 (3.49%) 20 (4.99%) 0.2930 
Patients with ≥1 ED Visit       
At 180 days post-index       
All-cause 268 (59.16%) 627 (57.63%) 0.5786 241 (60.10%) 244 (60.85%) 0.8285 
Liver-related (any position) 251 (55.41%) 535 (49.17%) 0.0257 226 (56.36%) 223 (55.61%) 0.8310 
1° – 4° Positions only 202 (44.59%) 412 (37.87%) 0.0140 184 (45.89%) 169 (42.14%) 0.2860 
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1° – 2° Positions only 153 (33.77%) 349 (32.08%) 0.5171 138 (34.41%) 139 (34.66%) 0.9408 
1° Position only 118 (26.05%) 276 (25.37%) 0.7801 106 (26.43%) 111 (27.68%) 0.6911 
HE-related (any position) 111 (24.50%) 254 (23.35%) 0.6263 100 (24.94%) 108 (26.93%) 0.5192 
1° – 4° Positions only 54 (11.92%) 119 (10.94%) 0.5776 50 (12.47%) 56 (13.97%) 0.5316 
1° – 2° Positions only 46 (10.15%) 102 (9.38%) 0.6361 42 (10.47%) 51 (12.72%) 0.3209 
1° Position only 40 (8.83%) 94 (8.64%) 0.9039 37 (9.23%) 47 (11.72%) 0.2488 
At 30 days post-index       
All-cause 146 (32.23%) 347 (31.89%) 0.8974 131 (32.67%) 134 (33.42%) 0.8218 
Liver-related (any position) 135 (29.80%) 286 (26.29%) 0.1584 120 (29.93%) 114 (28.43%) 0.6412 
1° – 4° Positions only 93 (20.53%) 203 (18.66%) 0.3955 84 (20.95%) 80 (19.95%) 0.7262 
1° – 2° Positions only 64 (14.13%) 168 (15.44%) 0.5114 58 (14.46%) 67 (16.71%) 0.3809 
1° Position only 45 (9.93%) 131 (12.04%) 0.2362 42 (10.47%) 53 (13.22%) 0.2294 
HE-related (any position) 47 (10.38%) 119 (10.94%) 0.7457 40 (9.98%) 48 (11.97%) 0.3661 
1° – 4° Positions only 20 (4.42%) 54 (4.96%) 0.6466 18 (4.49%) 24 (5.99%) 0.3416 
1° – 2° Positions only 15 (3.31%) 48 (4.41%) 0.3203 13 (3.24%) 23 (5.74%) 0.0881 
1° Position only 14 (3.09%) 42 (3.86%) 0.4619 13 (3.24%) 20 (4.99%) 0.2133 
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